AptaBio Therapeutics Inc
AptaBio Therapeutics Inc., a biopharmaceutical company, develops platform based drugs for intractable diseases. Its platforms include Oxidative stress modulation platform for developing therapeutic agents for diabetes complications, vascular diseases, neurodegenerative diseases, and intractable cancers by controlling oxidative stress; Cancer-associated fibroblast control platform for developing n… Read more
AptaBio Therapeutics Inc (293780) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.061x
Based on the latest financial reports, AptaBio Therapeutics Inc (293780) has a cash flow conversion efficiency ratio of -0.061x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-2.73 Billion) by net assets (₩44.61 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
AptaBio Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how AptaBio Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
AptaBio Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AptaBio Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Kuen Chaang Uppertech
TWO:6265
|
-0.047x |
|
Complete Logistic Services Bhd
KLSE:5136
|
0.029x |
|
AXIOS Sustainable Growth
NYSE:AXAC
|
-0.003x |
|
SCGJWD LOGISTICS PCL NON-VOTING DR
BK:SJWD
|
0.039x |
|
Birla Carbon (Thailand) Public Company Limited
BK:BCT
|
0.018x |
|
Unifique Telecomunicações S.A.
SA:FIQE3
|
0.109x |
|
Korvest Ltd
AU:KOV
|
0.045x |
|
VENTURE LIFE GRP LS -003
F:17V
|
N/A |
Annual Cash Flow Conversion Efficiency for AptaBio Therapeutics Inc (2017–2024)
The table below shows the annual cash flow conversion efficiency of AptaBio Therapeutics Inc from 2017 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩54.20 Billion | ₩-12.16 Billion | -0.224x | +2.32% |
| 2023-12-31 | ₩61.36 Billion | ₩-14.10 Billion | -0.230x | -76.05% |
| 2022-12-31 | ₩52.37 Billion | ₩-6.83 Billion | -0.130x | +9.57% |
| 2021-12-31 | ₩61.67 Billion | ₩-8.90 Billion | -0.144x | -174.59% |
| 2020-12-31 | ₩72.04 Billion | ₩-3.79 Billion | -0.053x | +34.20% |
| 2019-12-31 | ₩75.16 Billion | ₩-6.00 Billion | -0.080x | +16.38% |
| 2018-12-31 | ₩18.31 Billion | ₩-1.75 Billion | -0.095x | -268.19% |
| 2017-12-31 | ₩-31.54 Billion | ₩-1.79 Billion | 0.057x | -- |